Top 50 Biotech Startup Investors in Sweden in October 2024
A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotech startups based in Sweden. We rank investors based on the number of investments they made in Biotech companies from Sweden. We update this investor list every month.Top 50 Biotech Startup Investors in Sweden in October 2024
Investor | Biotech Sweden investments |
---|---|
Sciety | 14 |
Chalmers Ventures AB | 13 |
Almi Invest | 11 |
Industrifonden | 10 |
Navigare Ventures | 5 |
Karolinska | 5 |
HealthCap | 4 |
SEB Venture Capital | 4 |
Norrsken VC | 4 |
Inventure | 3 |
Partnerinvest Norr | 3 |
Novo Holdings | 3 |
Crowberry Capital | 3 |
Voima Ventures | 2 |
BackingMinds | 2 |
Segulah Medical Acceleration | 2 |
Boehringer Ingelheim Venture Fund | 2 |
Noaber | 2 |
Nina Capital | 2 |
EIR Ventures | 2 |
Andreas Ehn | 2 |
Hadean Ventures | 2 |
LIU Invest | 2 |
Additio Investment Group | 1 |
Colibri Ventures | 1 |
Fåhraeus Startup and Growth | 1 |
SmiLe Inject Capital | 1 |
ARCH Venture Partners | 1 |
Ferd | 1 |
TPG Growth | 1 |
I Love Lund | 1 |
Irrus Investments | 1 |
PULS | 1 |
Landegren Gene Technology | 1 |
Josefin Landgård | 1 |
Länsförsäkringar | 1 |
Inter Ikea | 1 |
Augmenta | 1 |
Ackra Invest | 1 |
Innovations Kapital | 1 |
Fibonacci Growth Capital | 1 |
LU Holding | 1 |
Almi Invest GreenTech | 1 |
Sting Capital | 1 |
Norrlandsfonden | 1 |
TVM Capital | 1 |
Sofinnova Partners | 1 |
Ysios Capital | 1 |
European Investment Bank | 1 |
FBG Invest | 1 |
Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Seed, Series A, Funding Round
- Sweden, Ukraine
Portfolio highlights
- NEOGAP Therapeutics — NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.
- PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
- Capitainer — Quantitative microsampling solutions for diagnostics, research and clinical trials. Microsampling you can trust.
We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS
Show more
Investment focus
- Software, Health Care, Energy
- Pre-Seed, Seed, Funding Round
- Sweden
Portfolio highlights
- Eneryield — We are specialized in predicting power outages with Sensorless Explainable AI. This enables proactive meassures.
- Korall Carbon Capture — Korall Carbon Capture is a pioneering company in Sweden specializing in Direct Air Capture (DAC) technology. KORALL offers a product in the form of a chemical blend that actively captures carbon dioxide as soon as it comes into contact with the air.
- ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.
ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion.
Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.
Show more
Investment focus
- Software, Health Care, Information Technology
- Funding Round, Seed, Pre-Seed
- Sweden, United States, United Kingdom
Portfolio highlights
- RemotiveLabs — RemotiveLabs is a developer of an automotive software development platform designed to streamline the vehicle manufacturing process.
- GAIA BioMaterials — GAIA BioMaterials is the manufacturer of a bio-degradable product that offers pouch, tray, and bottle products.
- Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Funding Round, Series A, Seed
- Sweden, United States, Denmark
Portfolio highlights
- Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
- Telness Tech — We help telcos maximize customer happiness and minimize OPEX through automation. Our proprietary, cloud-based, end-to-end BSS/OSS platform is connectivity ready in 64 countries.
- ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Funding Round, Seed, Series A
- Sweden, Denmark, United States
Portfolio highlights
- PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
- OssDsign AB — Giving patients back the life they deserve, Catalyst nanosynthetic bone graft, orthobiologics
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.
Show more
Investment focus
- Software, Information Technology, Financial Services
- Funding Round, Series A, Series B
- Sweden, Denmark, United Kingdom
Portfolio highlights
- Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
- EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
- Qvantum — Qvantum is driven by a passion for a sustainable future and we are changing the way the cities of Europe are heated.
We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.
Show more
Investment focus
- Software, Health Care, Food and Beverage
- Seed, Series A, Funding Round
- Sweden, United Kingdom, Germany
Portfolio highlights
- Syre — Syre is a textile impact company with a mission to decarbonize and dewaste the industry through textile-to-textile recycling at hyperscale.
- alcemy — Concrete is the most widely used building material on our planet. The only thing mankind uses more of is water. With a wave of urban development coming in the next few decades, concrete is also a rapidly growing trillion-dollar market. However, cement and concrete production is responsible for 8% of the global CO2 emissions, making its growth a bigcause for concern.Low-carbon concrete exists - but until now it has been too sophisticated to be produced reliably and on a large scale. It contains very little burnt limestone - responsible for the strength of concrete and CO2 emissions. This makes low-carbon concrete vulnerable to fluctuations in raw materials and operating conditions and thus difficult to produce with reliable quality. Adding to the challenge: the final quality of concrete can only be measured weeks AFTER it has been processed on the construction site - far too late to be corrected. This is why our world is still built on more robust, high-carbon concrete. Using alcemy's software, cement and concrete producers receive precise quality predictions already during production. Based on these prediction models, our AI identifies which production parameters need to be adjusted to mitigate the impact of fluctuations. Thus, the quality of cement and concrete can be optimized BEFORE delivery – for the first time in history.The result is significantly more consistent product quality, allowing producers to safely replace burnt limestone with less expensive, low-carbon materials found in nature. In this way, they can also avoid payments for CO2 emission certificates in the EU. Saving costs, bringing production processes up to speed for 21st century concrete recipes, and saving half of Europe’s CO2 emissions goes hand in hand at alcemy. Join us on our journey to make low-carbon concrete a reality!
- Vind AI — Experience the future of wind project planning with Vind AI. Design with real-time data, advanced optimization, and seamless collaboration.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- Finland, Sweden, Denmark
Portfolio highlights
- Leya AI — Feel and sound like an English native in 3 months
- Steep — Business intelligence for modern companies. Steep lets anyone on your team stay on top of your data.
- Reveel — Say goodbye to paper maps, brochures, and outdated audio guides. Reveel offers digital solutions for destinations such as UNESCO sites, sights, museums, cities, hotels and parks, taking the visitor experience to the next level. Become part of the smart destination movement, enhance the visitor experience, and discover the future of travel.
Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors.
Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.
Show more
Investment focus
- Software, Information Technology, Manufacturing
- Seed, Funding Round, Series A
- Sweden, United States
Portfolio highlights
- Flasheye — Flasheye has proven technology from the automotive, defense, and robotics industries into industrial applications.
- Elastisys — Succeed with your cloud native journey as an organization developing and operating software critical to our society. NIS2, ISO-27001, GDPR.
- Nordic Quick Systems — Nordic Quick Systems have been developing sprockets with segments that can be rotated and replaced. With their solution, machine maintenance can be carried out while both the chain and wheel body remain on the conveyor. Their products are developed in northern Sweden, a region strongly associated with well-qualified heavy industry. They work fortheir patented sprocket to become a new industry standard that streamlines the industry.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more
Investment focus
- Software, Information Technology, Gaming
- Seed, Series A, Pre-Seed
- Iceland, Denmark, Finland
Portfolio highlights
- Social First — We create games that are social experiences, span decades and extend beyond gaming; giving our players platforms to create meaningful relationships with people all across the world.
- Scaleup Finance — Improve your financial management
- Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more
Investment focus
- Biotechnology, Health Care, Medical Device
- Seed, Pre-Seed, Funding Round
- Finland, Sweden, Norway
Portfolio highlights
- NADMED — The standard of NAD measuring
- Betolar — Betolar is a new materials startup specialized in new geopolymer-based carbon-neutral construction materials for the construction industry and circular economy.
- Enifer — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
We help great minds unleash their full potential!
Show more
Investment focus
- Health Care, SaaS, Medical Device
- Seed, Funding Round, Pre-Seed
- Sweden, Denmark, Finland
Portfolio highlights
- Mylla — Mylla is a digital marketplace for buying and selling food from farm to table.
- Uniqkey — Uniqkey provides a security management platform that automates employee logins to make businesses secure and productive. It simplifies employee security while empowering companies with enhanced control over their cloud infrastructure, access security, and employee management.Recognized as the easiest tool, Uniqkey removes friction from employees’daily workflows by automating time-consuming authentication and security tasks, thereby increasing productivity. Its intuitive and user-friendly interface makes Uniqkey the perfect choice for employees.Uniqkey combats the most significant threats to company infrastructure by safeguarding critical systems and company credentials with state-of-the-art encryption. It also offers unique insights and a comprehensive view of IT infrastructure, employee access, and security scores, making it a valuable tool for IT teams to monitor security policies and confidently assess the impact of awareness campaigns.With powerful integrations and synergies with existing infrastructure such as Microsoft, IT managers can quickly provision or de-provision users for seamless onboarding and offboarding, all while protecting their entire IT infrastructure with advanced encryption.Trusted by 500+ European businesses and ranked as a Top 50 Global Security Solution by G2, our platform is becoming Europe's preferred business password and access management solution.
- NitroVolt — NitroVolt: the next generational step of sustainable ammonia.
Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series D, Series B
- Sweden, Germany, United States
Portfolio highlights
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Navinci Diagnostics — Navinci is a Swedish biotech company specializing in innovative in situ proximity ligation assay-based solutions for spatial proteomics.
- Signifier Medical Technologies — Driving Innovation in the Sleep MarketSignifier Medical Technologies (SMT) is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring. Pioneers in challenging the wisdom of conventional sleep apnoea and snoring treatments, we've created the first daytime therapy that tackles the root cause of sleep-disordered breathing by physiologically retraining the airway against collapse.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
- Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
- Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.
Noaber Ventures invests in initiatives that bring social transformations using information technology.
Show more
Investment focus
- Health Care, Medical, Fitness
- Seed, Series A, Funding Round
- The Netherlands, Israel, Sweden
Portfolio highlights
- Newsenselab (M-sense) — M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
- Elsa — Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.
- Alba Health — Discover your baby's gut health & microbiome for the best start in life.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more
Investment focus
- Health Care, Artificial Intelligence, Software
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Austria
Portfolio highlights
- Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Funding Round
- Denmark, Sweden, United States
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- ArgusEye — ArgusEye - Innovative Sensor Solutions - Real-time monitoring and control of biological systems and processes - Patented sensor technology
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.
Show more
Investment focus
- Software, Internet, Financial Services
- Seed, Angel, Pre-Seed
- United States, Sweden, Germany
Portfolio highlights
- Prog.AI — Prog.AI helps to find developers based on their technical proficiency, libraries they have used, or even just the contributions they have made to GitHub projects.
- Red Flag — Red Flag develops an automated accounting, expenses, and invoicing platform for SMEs.
- Single Technologies — Founded in Stockholm, Sweden, with its long tradition in fiber optics, ultra-sensitive fluorescence spectroscopy and DNA sequencing, SINGLE’s ambition is to become the instigator of 3-D Sequencing.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.
Show more
Investment focus
- Biotechnology, Information Technology, Health Care
- Funding Round, Seed, Pre-Seed
- Sweden
Portfolio highlights
- Cellfion — Cellfion provides sustainable materials for next level clean energy storage and conversion devices.
- Epishine — Epishine's goal is to be able to provide the world's most scalable, resource efficient, and affordable solar modules. Epishine sells light energy harvesting modules to manufacturers of wireless products. The modules are used to harvest light in any lighting conditions, turning light into usable power.
- LunaMicro — Technology company developing textile pumps based on electroosmosis and conducting polymers for a wide variety of applications including outdoor clothing, PPE, and medicine.
Value creation for Healthcare & Life Sciences Ventures through capital, expertise, international network.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A
- United Kingdom, Sweden
Portfolio highlights
- Orthox Ltd. — Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.
- Gedea Biotech — Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech's substance, GA101, is a natural substance that has always been part of their environment. It acts by lowering the pH as wellas providing a physical barrier protection and inhibiting biofilm formation. The first product will be a topical treatment of vaginal fungal infections.
- Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Colibri Ventures invest in early-stage life science companies and help accelerate their innovations into commercial products.
Show more
Investment focus
- Gaming, Wellness, Health Care
- Seed, Series A, Funding Round
- Sweden, Mexico
Portfolio highlights
- Mundi — Mundi provides financial, trade development, strategy, freight and reinventing international trade services.
- Mindforce Game Lab — Mindforce Game Lab creates meaningful games with characters that act as companions on the journey to better health.
- Pixelgen Technologies — Understand the role of proteins in cellular organization with spatial proteomics. Get ahead in the field of proteomics with us.
Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.
Show more
Investment focus
- Medical, Health Care, Organic Food
- Funding Round, Seed
- Sweden
Portfolio highlights
- Saveggy — Saveggy develops a bio-based edible vegan coating for fruit and vegetables eliminating plastic while keeping its protecting properties.
- Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
- Nygen Analytics — Nygen empowers researchers to unlock insights from single-cell RNA-seq data with accessible, no-code solutions, facilitating reproducible transcriptomic research.
SmiLe Inject Capital is an angel investment company to focus exclusively on early-stage life science companies.
Show more
Investment focus
- Medical, Genetics, Analytics
- Seed
- Sweden
Portfolio highlights
- Nygen Analytics — Nygen empowers researchers to unlock insights from single-cell RNA-seq data with accessible, no-code solutions, facilitating reproducible transcriptomic research.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Vilya — Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Rippl Care — Dementia care for seniors, ready when you are
Ferd er et familieeid investeringsselskap som er eid av femte og sjette generasjon Andresen.
Show more
Investment focus
- Energy, Software, Manufacturing
- Funding Round, Private Equity, Post-IPO Equity
- Norway, Sweden, United States
Portfolio highlights
- Ludenso — Ludenso is a software developer of AR solutions for the education industry. To make education more creative and engaging, we are giving editors, authors, and teachers the power to bring their learning resources to life through 3D models, animations, videos, and audio support. This is made possible through the Ludenso Studio, where they can createinclusive learning experiences that enables students to learn in their own way.
- wheel.me — The first and only autonomous wheel in the world. The innovation transforms anything into an autonomous mobile robot with minimal effort and without the need to alter its design or form. The company was founded in 2013 and is headquartered in Oslo, Norway.
- Nofence — Nofence is a system virtual fencing for grazing animals. Virtual fencing of livestock has been a concept long discussed in academia. The Norwegian ag-tech startup Nofence has since 2011 developed and patented a solution for virtual fencing that has proven to work. The customers say that this will become a real gamechanger for livestock managementsince pastures can easily be defined by a few clicks on a tablet/smartphone. The herd is then safely fenced in and can be monitored. The system will send notifications if something happens. From the global food security perspective, this solution will make it much easier to utilize the uncultivated land for varied and healthy pasture, and make it possible to produce more food on cultivated land.
A leader in the alternative asset space, TPG was built for a distinctive approach, managing assets through a principled focus on innovation.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series C, Series B, Private Equity
- United States, India, China
Portfolio highlights
- Fibe — Get instant loans up to Rs. 5L with tenures up to 24 months & rates as low as 2.5% p.m. Check your eligibility now.
- Homrich Berg — Homrich Berg is a personal wealth management firm based in Atlanta, GA helping families protect, grow, and manage their wealth since 1989.
- Dr. Agarwal's — Dr. Agarwals eye hospital with best eye specialist and 135+ hospitals in India providing best eye disease treatment since 1957. Book an appointment now!
I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds
Show more
Investment focus
- Analytics, Biotechnology, Market Research
- Seed, Pre-Seed, Funding Round
- Sweden
Portfolio highlights
- Parlametric — Parlametric combines new technology with scientific methods in language analyzing. That means we go deeper than other market analysts.
- Katam Technologies — Development of drone measurement and cloud-based evaluation service providing high precision forestry data using a mobile phone or drone.
- Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.
Show more
Investment focus
- Biotechnology, Health Care, Medical Device
- Seed, Funding Round, Series A
- Ireland, Sweden, United States
Portfolio highlights
- Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
- ByoWave — ByoWave has developed the Proteus Controller, a modular, accessible video game controller for disabled and non-disabled gamers.
- Bluedrop Medical — Thermal and visual assessment in a single scan. Award winning, patented design.
PULS is specialized on DIN rail power supplies for industrial applications. We set standards in terms of efficiency, reliability, size and life time.
Show more
Investment focus
- Biopharma, Health Care, Biotechnology
- Funding Round
- Sweden
Portfolio highlights
- Adenovir Pharma — Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes.Adenovir Pharma was founded by researchers at the department of Virology, UmeÃ¥ University, Sweden and P.U.L.S. AB which acts as an incubator and financer for early stage projects within life science. Adenovir Pharma islocated in Helsingborg Sweden in one of Europe’s premier biotechnology regions, Medicon Valley. The initial development has been conducted at the University of Lund, Department of Organic Chemistry and at the University of UmeÃ¥, Department of Virology and in collaboration with P.U.L.S. AB and external service providers.With unique patented technology and own product concepts, Adenovir Pharma aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC).
Landegren Gene Technology
Show more
Investment focus
- Health Care, Biotechnology, Health Diagnostics
- Series A
- Sweden
Portfolio highlights
- Navinci Diagnostics — Navinci is a Swedish biotech company specializing in innovative in situ proximity ligation assay-based solutions for spatial proteomics.
Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.
Show more
Investment focus
- Health Care, Medical, Women's
- Seed, Angel, Pre-Seed
- Sweden, France
Portfolio highlights
- Estmn — Estrid is an online portal that offers women's personal care products.
- Lassie — Lassie is the first proactive and preventive pet insurance company that wants to help pet owners take better care of their pets
- Elsa — Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.
Länsförsäkringar is a Swedish group of public insurance companies.
Show more
Investment focus
- Manufacturing, Apps, Mobile
- Seed, Funding Round
- Sweden
Portfolio highlights
- Wrapp — THE NEW STANDARD HAS ARRIVED. Wrapp is The New Standard for rewarding purchases and customer loyalty. The end to an era of irrelevant advertising and outdated memberships. Wrapp connects to our users’ payment cards, and analyzes transactions to learn their buying behavior. This way, our users only get rewards from brands they're interestedin. And by sticking to cashback returns, we make sure they get rewards they actually find useful. Simply put, we put purchasing power in the hands of consumers, and meaningful marketing in the hands of brands.
- Altris — Altris is a leading developer of sodium-ion batteries, offering superior performance and sustainability. Our innovative energy storage solutions are made from abundant and renewable materials, revolutionizing the way we power the world. Discover our cutting-edge technology today.
- Vindmark — Innovativ effektiv vindkraft
Inter IKEA Group's aim is to secure continuous improvement, development, expansion and a long life of the franchising operation.
Show more
Investment focus
- Software, Furniture, Health Care
- Funding Round, Seed, Corporate Round
- Germany, Sweden, Denmark
Portfolio highlights
- nyris — Our custom search engines make it easy for people to find products, spare parts, and components for industry and eCommerce
- NORNORM — NORNORM is a subscription-based furnishing model, letting your business adapt to the needs of tomorrow. Beautiful, affordable and fully circular.
- Seprify — Enabling sustainable products
Augmenta will invest in early stages of companies with unique products and strong growth potential.When portfolio companies have a fully developed product or service that is ready for commercialization, will Augmenta to leave their interests in portfolio companies. Exactly when this will happen will vary and depend on each company's uniquesituation.
Show more
Investment focus
- Biopharma, Health Care, Biotechnology
- Funding Round
- Sweden
Portfolio highlights
- Adenovir Pharma — Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes.Adenovir Pharma was founded by researchers at the department of Virology, UmeÃ¥ University, Sweden and P.U.L.S. AB which acts as an incubator and financer for early stage projects within life science. Adenovir Pharma islocated in Helsingborg Sweden in one of Europe’s premier biotechnology regions, Medicon Valley. The initial development has been conducted at the University of Lund, Department of Organic Chemistry and at the University of UmeÃ¥, Department of Virology and in collaboration with P.U.L.S. AB and external service providers.With unique patented technology and own product concepts, Adenovir Pharma aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC).
Ackra Invest AB is a venture capital and private equity firm specializing in late venture, growth capital and turnaround investments. The firm does not have a sector preference and seeks to invest in small and middle sized companies based in Norrland; the Northern region of Sweden. It does not provide loans or invest in seed or early venture. Thefirm takes minority stakes, between 10 percent and 49 percent and invests between SEK1 million ($0.13 million) and SEK8 million ($1.02 million). It invests in equity or convertible loans and can perform co-investments. The firm seeks to exit its investments within seven years. Ackra Invest AB was founded in 2005 and is based in Skellefteå, Sweden.
Show more
Investment focus
- Manufacturing, Mining, Chemical
- Funding Round, Seed
- Sweden
Portfolio highlights
- Xore — Xore AB has develops and sells analyzers to enrichment plants in the mining industry.Xore is one of the world’s leading suppliers of on-stream analyzers and related services to the mining industry. Xore is the natural first choice when investing in equipment for on-stream analysis of pulp and liquids. Our product brand is Boxray™. Xore is agenuine Swedish engineering technology company based in Skellefteå in northern Sweden.
- Protab AB — Protab specializes in machining, turning and milling and manufactures details for the hydraulic and forest industry. Another important part of the business is system delivery, where the company also assembles the details that were manufactured.Protab manufactures components primarily for the hydraulics and forestry industries. System deliveries,where the company assembles manufactured components, form another important part of the operation. We also do value flow analyses to improve the efficiency of our customers' businesses. How can we make things better for you?
- Fortlax AB — Fortlax is Northern Sweden's data center with three world-class facilities just outside Piteå. We help companies grow using smart IT and cloud services. We store data in highest-class facilities at a location where risk analysis shows extremely low risk of natural disasters. In addition, we operate all our facilities with 100% green energy anduse natural cooling for large parts of the year. Fortlax AB has over the past fiscal year more than tripled its revenue and shows profit.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Series B, Series C
- Sweden, Denmark, United States
Portfolio highlights
- Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Fibonacci Growth Capital is a venture capital investment firm.
Show more
Investment focus
- Biotechnology, Manufacturing, Medical Device
- Seed
- Sweden
Portfolio highlights
- Pixelgen Technologies — Understand the role of proteins in cellular organization with spatial proteomics. Get ahead in the field of proteomics with us.
LU Holding is a Lund University’s investment company.
Show more
Investment focus
- Biotechnology
- Pre-Seed
- Sweden
Portfolio highlights
- Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Almi Invest GreenTech is a venture capital company and an active start-up investor.
Show more
Investment focus
- Waste Management, Energy, Manufacturing
- Funding Round, Seed, Series A
- Sweden
Portfolio highlights
- Zparq — Zparq designs and manufactures marine electric propulsion products.
- Modvion — Modvion is a Swedish/ American Engineering and Industrial Design company developing modular designs in renewable engineered wood product materials to simplify and improve construction logistics.Their current area of focus is in wind tower technology. Modvion´s patented module technology enables significantly decreased cost, efficienttransportation and streamlined installation of towers exceeding 120 m. Ultimately, this results in increased cost efficiency in the harvesting of wind resources.
- EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
Sting – Stockholm Innovation & Growth enables talented people to turn their ideas into sustainable businesses. The support they offer includes qualified coaching in business development, a business angel network, a venture capital fund, a recruitment service, and an international network of investors, business contacts and experts. Itcontribute to the success of Sweden’s future technology companies by helping them to grow and compete internationally.
Show more
Investment focus
- Software, Apps, Medical
- Funding Round, Seed, Pre-Seed
- Sweden
Portfolio highlights
- Prion — Prion makes it quick and easy for the preschool staff to give parents insight into what happens at preschool - together with the children. The app is available free for iPhone, Android and iPad.
- Texelio — Texelio a company who is set to redefine financial market news by developing AI which empowers the customers of Retail banks, Online Brokers and Investment Service platforms.
- Minnemera — Minnemera develops digital neurocognitive tests.
Norrlandsfonden is a foundation that promotes the development of companies with growth ambitions. They offer flexible prime loans for new establishments, development, and expansion. They provide the opportunity for offensive and forward-looking investments and enable companies and people to grow.
Show more
Investment focus
- Software, Information Technology, Web Hosting
- Funding Round, Seed, Debt Financing
- Sweden, United States
Portfolio highlights
- Big Akwa — Big Akwa is a food-tech innovation start-up that economically and environmentally revolutionizes land-based aquaculture by introducing industrial symbiosis between the aquaculture and forest industry.
- Flasheye — Flasheye has proven technology from the automotive, defense, and robotics industries into industrial applications.
- Crosser — Low Code Platform, purpose-built for real-time processing of streaming data for Industrial IoT and Intelligent Workflows.
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Funding Round, Series C
- United States, Germany, United Kingdom
Portfolio highlights
- Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
- Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
- Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
- Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
- Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Spain, United States, Switzerland
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Debt Financing, Post-IPO Debt, Funding Round
- France, Germany, The Netherlands
Portfolio highlights
- Rohlik — Rohlik is an innovative grocery delivery startup that offers a 90-minute same-day delivery service. Since its inception, Rohlik has been growing and is on track to EUR 300 mil. revenues in 2020. Rohlík was founded in 2014 by Marek Sacha and Tomas Cupr and is headquartered in Karlín, Hlavni mesto Praha, Czech Republic.
- Eldrive — Eldrive Makes electric vehicle charging simple: our intelligent platform automates the entire charging process and infrastructure, ensuring a smooth experience for drivers and businesses.
- ABN AMRO Bank — Als bank leggen wij de focus op inclusiviteit, duurzaamheid, sociaal ondernemen, innovatie, dagelijkse bankzaken en meer.
FBG Invest
Show more
Investment focus
- Biotechnology, Manufacturing, Food Processing
- Funding Round
- Sweden
Portfolio highlights
- Mycorena — Fungi-based, next-generation vegan protein. A food manufacturing solution superior to plants, using significantly less resources.
Investors by industry
Energy
Climate
Health Care
Gaming
Hardware
Artificial intelligence
Impact
Proptech
Marketplace
Community
FinTech
Google
Consumer
Biotech
EdTech
Sustainability
Venture Capital
Beauty
B2B
Photography
Finance
Real Estate
Big Data
Web3
Clean Energy
Oil and Gas
Video Games
Social Media
Food and Beverage
Medical
Email
Publishing
Art
Wellness
Education
Music
Mobile
Payments
Franchise
Social Network
Local
Fashion
Internet
Digital Media
Construction
Organic Food
Manufacturing
eSports
Sports
Enterprise Software
Retail
Legal
Android
Financial Services
Platforms
Mobile Advertising
Infrastructure
Biotechnology
Wine And Spirits
Hospitality
Fitness
Travel
Recruiting
Cannabis
CleanTech
Medical Device
Crowdfunding
Transportation
Mobile Apps
InsurTech
Social
Enterprise
Automotive
Non Profit
LGBT
Life Science
Theatre
Film
Sporting Goods
Renewable Energy
SaaS
Restaurants
Software
Social Impact
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Ireland
New Zealand
Canada
United States
Spain
Indonesia
Singapore
South Africa
Africa
Qatar
Europe
LATAM
Middle East
Sri Lanka
Asia
Armenia
Vietnam
China
Japan
Saudi Arabia
Brazil
Oceania
Czech Republic
Ecuador
Barbados
Costa Rica
Finland
Morocco
Malta
Belarus
France
Mali
Malaysia
Estonia
Italy
Hong Kong
Peru
Denmark
Lithuania
Myanmar
Gibraltar
Lebanon
Kuwait
Cayman Islands
Chile
Cambodia
Israel
Bermuda
Belize
Panama
Georgia
Greece
Mexico
Egypt
Kazakhstan
Liberia
Hungary
Jersey
Philippines
Ethiopia
Norway
Faroe Islands
Algeria
Mauritius
Ghana
Kenya
Belgium
Croatia
Liechtenstein
Nicaragua
Bulgaria
Turkey
Bahrain
Serbia
Rwanda
Dominican Republic
El Salvador
Nigeria
Venezuela
Ukraine
Portugal
Sierra Leone
Zimbabwe
Sweden
Taiwan
Senegal
Azerbaijan
Namibia
Iceland
Uruguay
Uganda
Iraq
Bahamas
Tunisia
San Marino
United Arab Emirates
Slovenia
Zambia
Honduras
Uzbekistan
Russian Federation
Bolivia
Isle of Man
Seychelles
Luxembourg
Thailand
Puerto Rico
Tajikistan
Togo
Albania
Poland
Pakistan
Tanzania
Grenada
Jordan
Romania
Argentina
Bangladesh
Austria
Latvia
Cyprus
Oman
Cameroon
Switzerland
Guatemala
Colombia
Marshall Islands
Investors in Sweden by industry
Restaurants
Crowdfunding
Artificial intelligence
Sporting Goods
Financial Services
Big Data
Cryptocurrency
Finance
Payments
Organic Food
Social
Video Games
Food and Beverage
Medical Device
Biotechnology
Wellness
Internet
Social Media
Manufacturing
Digital Media
Art
Music
Mobile
Android
Blockchain
Legal
Construction
Software
Social Network
Enterprise Software
eSports
Fitness
Sports
Hospitality
CleanTech
Travel
InsurTech
Enterprise
FinTech
Consumer
Health Care
Sustainability
Climate
EdTech
Energy
SaaS
Impact
Proptech
Marketplace
Retail
Hardware
Infrastructure
Beauty
B2B
Web3
Life Science
Photography
Clean Energy
Publishing
Education
Recruiting
Platforms
Real Estate
Mobile Apps
Automotive
Biotech
Community
Gaming
Transportation
Medical
Fashion
Agriculture (agtech)
Social Impact
Media (entertainment)
Renewable Energy